Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

Authors
Category Primary study
JournalBlood
Year 2023
This article has no abstract
Epistemonikos ID: 7f96d42ad1a5553a457d16fb92d2218d98f49ce4
First added on: Feb 17, 2025